GINZA NOA CLINIC
Tokyo, Japan International Patient Support
Contact Us

How Are Stem Cells Grown?

Short answer: Scientists grow stem cells in a nutrient liquid called culture medium, using controlled laboratory conditions that let the cells divide. They replace the medium and move cells into fresh vessels as cultures become crowded; this transfer is called passaging. The medium, surface, and other conditions depend on the cell type and whether the aim is to keep cells unspecialized or make a specific cell type Stc basics. Cells intended for treatment also need manufacturing controls and batch checks. Growing cells is not, by itself, proof that a treatment works.

From sample to growing culture

The starting material may be a tissue sample or an existing cell line. Holoclar, an EU-authorised treatment for burn-related limbal stem cell deficiency in adults, starts with just 1–2 mm² of healthy tissue from the patient’s limbus, the rim of the cornea. Its cells are expanded in a laboratory before the final eye implant is made Holoclar.

How Are Stem Cells Grown?

Blood-forming stem cells can come from bone marrow, circulating blood after mobilization, or umbilical cord blood. After transplantation, they establish blood production in the marrow. Collection and transplantation are not synonyms for laboratory culture expansion: the treatment description must say whether an expansion step is involved Stem cell transplant.

Embryonic stem cells and induced pluripotent stem cells can produce many types of body cells. Scientists make induced pluripotent stem cells by reprogramming ordinary adult cells. Adult tissue stem cells generally have a narrower range of possible cell types What are stem cells. A culture protocol for one population cannot simply be applied to every product called a “stem cell” treatment.

Stage What happens What to check for a treatment batch
Collection or starting stock Staff obtain tissue, collected cells, or a banked cell line Exact tissue, cell type, and patient or donor identity
Isolation and preparation Staff separate the intended population from the starting material Whether the preparation is a mixed concentrate or a culture-expanded population
Culture and feeding Cells grow in medium suited to that population; staff replenish the medium and monitor the culture Which facility, medium, and manufacturing process were used
Passaging Staff transfer cells into fresh vessels to continue growth without overcrowding Passage history and how batches remain separate and traceable
Batch testing Staff assess identity, viable cell count, contamination, and any product-specific function requirements Results for the actual batch, dates, and release criteria
Storage and preparation for use The process may include freezing, transport, thawing, and further preparation Which checks apply to the final preparation being administered

The culture and passaging stages describe laboratory growth, not a universal treatment schedule Stc basics. A same-day preparation may not have undergone culture expansion. Ask whether the cells were merely separated or concentrated, or actually grown through cell division. In U.S. regulation, “minimal manipulation” has specific tests concerning changes to tissue or cell characteristics; it is not a statement of approval or effectiveness Regulatory considerations human cells tissues and cellular and tissue based products minimal.

What cells need in the lab

Culture medium supplies nutrients and signals that support growth. Many stem cells grow attached to a suitable surface, while the precise culture system depends on the population. Staff monitor the culture and transfer cells before crowding disrupts growth. NIH describes repeated passaging over many months for research cultures; that is not a promised turnaround time for a clinical batch Stc basics.

Expansion and differentiation are different tasks. Expansion increases cell numbers. Differentiation produces more specialized cells. Scientists can change medium composition, the culture surface, or gene expression to direct pluripotent cells toward particular cell types. A larger population does not automatically become the tissue a patient needs Stc basics.

Clinical manufacture takes place in an appropriate cell processing facility, not simply by leaving a sample in a dish. In Japan, the Act on the Safety of Regenerative Medicine governs specified research and provision of regenerative medicine, while the Pharmaceuticals and Medical Devices Act provides a separate framework for manufacturing and marketing regenerative medical products 0003.

How long growing takes

There is no single culture time that applies to all stem cells. The starting population, required number, differentiation steps, and manufacturing process determine the schedule. Research cell lines may be maintained through repeated passages for months; patient-specific products follow their own production process Stc basics.

Holoclar illustrates why freezing does not always mean the product is ready to administer. EMA describes laboratory expansion followed by freezing until surgery is confirmed. The thawed cells are then grown on a fibrin membrane to make the final product, which is surgically implanted in the eye Holoclar.

Blood stem cell infusion takes 1–5 hours, and full immune recovery takes several months after an autologous transplant or 1–2 years after an allogeneic or syngeneic transplant. These are administration and recovery times, not laboratory growing times Stem cell transplant.

How a batch is checked

For cells intended for treatment, ask what establishes the cell identity, how viable cells are counted, which contamination tests are performed, and which functional tests the product requires. Testing and monitoring belong throughout manufacture, not only at the end. A viable-cell count cannot establish clinical benefit, and no single result should be treated as a guarantee of safety. FDA describes contamination, unwanted tissue growth, and immune reactions among the risks of unapproved regenerative products, including products made from a patient’s own cells Important patient and consumer information about regenerative medicine therapies.

At a pre-treatment appointment: Ask the clinician to walk through the records for your actual batch, rather than a sample certificate. Match the batch identifier across the processing record, test report, and planned administration. Ask where the records show the cell type, culture dates, facility, and responsible team. For a frozen preparation, ask whether the reported count was measured before freezing or after thawing, and what supports the final dose. If a result is pending or a field is missing, ask what the release rules allow and request an explanation before consenting. This is a document-checking scenario, not a report of a particular patient’s experience.

The same questions help when you compare hospitals. They focus the discussion on the preparation you may receive, rather than a laboratory’s general claims.

Growing cells versus proving a treatment

Holoclar is an example of a lab-grown product with a narrow authorised indication and a surgical delivery method. It does not establish that other cells, sources, or injection routes work for unrelated diseases Holoclar. Japan’s provision plans and product approvals also belong to different regulatory systems 0003.

Evidence or regulatory record What it actually tells you
Japan’s provision-plan counts MHLW recorded 6,743 treatment plans and 85 research plans as of 30 June 2026. These are plan counts, not numbers of proven treatments or patients helped 001590173.pdf.
Japan’s regenerative-product framework PMDA distinguishes cell/tissue-based therapies from gene therapies and describes product-specific approval pathways, including conditional and time-limited approval. An approval applies to a named product and use, not to all stem cell injections 000280868.pdf.
Knee osteoarthritis evidence A 2025 Cochrane review included 25 randomized trials with 1,341 participants overall; 8 trials with 459 participants compared injections with placebo. The preparations and doses varied CD013342_what are benefits and risks stem cell injections knee osteoarthritis.

For knee osteoarthritis injections, the review found low-certainty evidence of slightly better pain and function than placebo. At six months, average pain was 3.3 versus 4.5 on a 0–10 scale, a 1.2-point difference. The review’s evidence search ran to 15 September 2023. No included study assessed radiographic progression, so these findings do not demonstrate cartilage regrowth; safety also remained uncertain CD013342_what are benefits and risks stem cell injections knee osteoarthritis. The results cannot validate every clinic’s cultured-cell preparation.

Cells dividing in a dish, passing a laboratory test, and improving a patient’s health are three different claims. Each needs its own evidence.

Collection and delivery add risks of their own, including pain, bleeding, infection, and complications of the procedure used. For donor-cell treatments, ask about compatibility, infectious-disease screening, and any immune-suppression requirements specific to that treatment. Using your own cells does not eliminate processing or treatment risks Important patient and consumer information about regenerative medicine therapies.

Questions before treatment

International stem cell guidelines emphasize rigor, oversight, and transparency in research and clinical translation Guidelines. Ask for written answers to these questions:

  • What is the exact cell type and starting tissue, and is the material my own or a donor’s?
  • Were the cells culture-expanded, merely separated, or taken from an existing frozen stock?
  • Which facility grew them, for how long, and under whose responsibility?
  • Which results and release criteria apply to my batch, including any preparation after thawing?
  • Is this an authorised product, a filed treatment plan, or a clinical trial, and what is its identifier and exact indication?
  • What human evidence matches this cell preparation, diagnosis, dose, and delivery route, and what follow-up and adverse-event arrangements apply?

Questions about a proposed cell preparation?

Use the enquiry form to ask what information is available about the process and appointment arrangements. A treatment decision requires review by a qualified physician.

Send an enquiry

The bottom line

Stem cells grow by dividing in a controlled culture system, with suitable medium, monitoring, and passaging. Directing them into a particular cell type is a separate step Stc basics. Holoclar shows how a 1–2 mm² sample can enter a defined manufacturing process, but its process and indication do not apply to every stem cell offer Holoclar.

Stem cells’ ability to renew themselves and form specialized cells explains their research value Stemcells. Before considering treatment, establish exactly what was grown, how the final batch was checked, and what human evidence supports its intended use.

This article provides general information, not personal medical advice. It does not report a laboratory visit, a patient’s treatment, or a clinician’s first-hand experience.